S U M M A R Y Double-label fluorescent immunohistochemistry (IHC) is frequently used to identify cellular and subcellular co-localization of independent antigens. In general, primary antibodies for double labeling should be derived from independent species. However, such convenient pairs of antibodies are not always available. To overcome this problem, several methods for double labeling with primary antibodies from identical species have been proposed. Among them are methods using monovalent secondary antibodies, such as Fab fragments. Soluble immune complexes consisting of primary and monovalent secondary antibodies are first formed. After absorption of the excess secondary antibody with nonspecific immunoglobulin, the immune complexes are applied to sections. By this procedure, unwanted cross-reaction between false pairs of antibodies is avoidable. However, soluble immune complexes often show reduced or no immunoreactivity to antigens on sections. I noted that antigen retrieval (AR) of tissues by heating often but not always showed improved immunoreactivity for soluble immune complexes. Here I demonstrate the examination of conditions for this soluble immune complex method using AR-treated sections and show examples of double-label fluorescent IHC with identical species-derived primary antibodies.
D emonstration of co-localization of independent antigens in identical cells or cell compartments is one of the essential techniques in cell biology. For this, usually double and occasionally triple immunohistochemical (IHC) and immunocytochemical (ICC) labeling are performed. Antibodies derived from different animal species are easily distinguished by secondary antibodies against species-specific immunoglobulins. In general, double-labeling techniques are based on this principle, and sets of primary antibodies derived from different animal species are used. However, when pairs of primary antibodies are antibodies derived from the same species, the general double-labeling methods cannot be used.
To enable double labeling with primary antibodies from the same species, several methods have been developed: (a) adjacent thin sections are separately stained and compared (serial sectioning and mirror sectioning methods; Osamura et al. 1981; Tsutsumi 1988; Stevenson and Pflüger 1994) ; (b) primary antibodies are monoclonal antibodies belonging to different immunoglobulin subclasses (Tidman et al. 1981) ; (c) primary antibodies are directly labeled with enzymes, fluorophores, or haptens such as biotin (direct labeling method; Valnes and Brandtzaeg 1982; Boorsma 1984; Van der Loos et al. 1989; Würden and Homberg 1993) ; (d) primary and secondary antibodies are sequentially applied and stained (sequential staining method; Falini et al. 1986; Wessel and McClay 1986; Franzusoff et al. 1991; Lewis Carl et al. 1993; Negoescu et al. 1994; Hontanilla et al. 1997) ; (e) highly sensitive tyramide signal amplification is used to distinguish primary antibodies (Shindler and Roth 1996; Hunyady et al. 1996; Brouns et al. 2002; Uchihara et al. 2003) . Method a is suitable only for large cells spanning to two sections, which limits the extent of application. Method b requires highly specific second-Ino ary antibodies to immunoglobulin subclasses and is inapplicable to polyclonal antibodies or to monoclonal antibodies belonging to the same subclass. Although method c is applicable in any case, the preparation of labeled primary antibodies is laborious. Method d is superior to the former methods in the extent of application and in the easiness of procedure, but it is not so easy to exclude false-positive staining by secondary antibodies' crossreaction or insufficient removal of first primary antibodies. To avoid secondary antibodies' crossreaction, methods using monovalent secondary antibodies, especially using Fab fragments, have been reported (Wessel and McClay 1986; Franzusoff et al. 1991; Lewis Carl et al. 1993; Negoescu et al. 1994) , and kits for these methods are supplied from some manufacturers, such as Zenon labeling reagents from Molecular Probes (Eugene, OR). Method e works when a first primary antibody is applied at a low concentration, which is detectable by tyramide amplification but not with a fluorescently labeled secondary antibody. A second primary antibody is applied at a normal concentration. Because the second primary antibody is applied after tyramide amplification of the first primary antibody, these two antibodies can be distinguished. Although this system is excellent, it is applicable to double but not to triple labeling.
On the other hand, immunostaining methods using soluble immune complexes consisting of primary and secondary antibodies have been reported (Tuson et al. 1990; Krenács et al. 1991; Eichmüller et al. 1996) . By combining the method using monovalent secondary antibodies and that using soluble immune complexes, an improved method for double-label IHC with identical species-derived primary antibodies is obtained.
With this method, secondary antibodies' crossreaction is avoidable and the required amount of secondary antibodies can be saved. There are two procedures for this double-labeling method. The reaction is completed by two-step incubation as follows ( Figure 1A ): a first primary antibody (M) is applied to sections, followed by the reaction with a first monovalent secondary antibody (X). A soluble immune complex consisting of a second primary antibody (N) and a second monovalent secondary antibody (Y) is formed before application to sections. After absorption of the excess second secondary antibody (Y) with nonspecific immunoglobulin, the immune complex is applied to sections. Alternatively, the reaction is completed by onestep incubation ( Figure 1B) : two soluble immune complexes consisting of a primary antibody and a monovalent secondary antibody are separately formed, and the excess secondary antibodies are absorbed. Then the immune complexes are applied to sections.
The critical point in the above methodology is whether soluble immune complexes are able to react with antigens in sections. In many cases, the reactivity of soluble immune complexes in sections is greatly reduced or sometimes completely lost. I previously reported a new antigen retrieval (AR) method by heating (Ino 2003 (Ino ,2004 , which was originally developed for the enhancement of immunoreactivity by the general sequential labeling method (primary and secondary antibodies are sequentially applied to sections). I demonstrate here that AR of tissues by heating often enhanced the reactivity of soluble immune complexes, even though this effect was not always observed. In addition, I show examples of double-label fluorescent IHC with identical species-derived primary antibodies by two-step and one-step incubation. Two-step incubation procedure. A first primary antibody (M) is reacted with an antigen (m) in sections and then a first monovalent secondary labeled with X is applied. After the first reaction, an immune complex consisting of a second first antibody (N) and a second monovalent secondary antibody labeled with Y is applied. (B) One-step incubation procedure. Two immune complexes are separately formed and then applied to sections. In each procedure, the excess secondary antibodies in the immune complexes are absorbed with nonspecific immunoglobulin before application to the sections.
Materials and Methods

Preparation of Tissue Sections
Male Sprague-Dawley rats (body weight 250-300 g) were perfused via the heart with 4% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.5, under deep pentobarbital anesthesia. All animals were treated and cared for in accordance with the Chiba University School of Medicine guidelines pertaining to the treatment of experimental animals. Brains and dorsal root ganglia (DRG) were collected. Forebrains and brainstems were coronally sliced at 5-mm thickness and cerebella were sagittally cut. The tissues were postfixed in the same fixation solution at 4C for 1 day, incubated in PBS at 4C for 1 day, and incubated in 30% sucrose in PBS at 4C for 1 day. The tissues were embedded in OCT Compound (Sakura Fine Technical; Tokyo, Japan) and frozen with dry ice. Frozen sections were cut with a cryostat at 10-m thickness and mounted on glass slides coated with poly-l -lysine. After drying in a vacuum desiccator for more than 1 day, the sections were used for IHC. For some tissues, AR by heating en bloc was performed after postfixation, as follows.
AR by Heating
AR by heating en bloc was performed for some tissues as previously described (Ino 2003 (Ino ,2004 . After postfixation, tissues were incubated in distilled water at 4C for 1 day and boiled in distilled water for 3 min. The tissues were then placed in ice-cold 30% sucrose in PBS and incubated in the same solution at 4C for 1 day. Frozen sections were prepared as above.
Primary Antibodies
Primary antibodies are listed in Table 1 . In total, 12 antibodies were tested, among which five monoclonal antibodies were raised in mouse (IgG 1 ) and seven polyclonal antibodies were raised in rabbit or guinea pig.
Divalent Secondary Antibodies
Divalent secondary antibodies are listed in Table 2 . Biotin-conjugated horse anti-mouse IgG(H ϩ L), goat anti-rabbit IgG(H ϩ L), and goat anti-guinea pig IgG(H ϩ L) antibodies (Vector Laboratories; Burlingame, CA) were used.
Preparation of Monovalent Secondary Antibodies
Monovalent secondary antibodies are listed in Table 2 . Affinity-purified goat polyclonal anti-mouse IgG(Fc) (Rockland; Gilbertsville, PA), anti-rabbit IgG(Fc) (Jackson Immu-noResearch Laboratories; West Grove, PA), anti-guinea pig IgG(Fc) (Jackson) and anti-mouse IgG(H ϩ L) (Jackson) antibodies were used. Fab fragments were prepared with Immo- bilized Papain (Pierce; Rockford, IL) according to the manufacturer's protocol. In brief, the antibodies were dialyzed against 20 mM sodium phosphate and 10 mM EDTA, pH 7.0. The dialyzed antibodies (2 mg) were digested with a 0.5 ml slurry of Immobilized Papain in 20 mM sodium phosphate, 10 mM EDTA, and 20 mM cysteine-HCl, pH 7.0, for 6 hr at 37C. The reaction mixtures were applied to a HiTrap Protein A HP 1-ml column (Amersham Biosciences; Piscataway, HJ) and unbound fractions were collected. Buffer change to 20 mM sodium phosphate, pH 7.0, and concentration were carried out by filtration with Ultrafree C3LGC columns (Millipore; Bedford, MA). The Fab fractions (1.8-2.0 mg/ml) were labeled with 20 excess mols of sulfosuccinimidyl 6-(biotinamide) hexanoate (ImmunoPure NHS-LC-Biotin; Pierce) or digoxigenin (DIG)-3-O -methylcarbonyl-␣ -aminocapronic acid-N -hydroxysuccinimide ester (Roche Diagnostics, Basel, Switzerland). The former labeling reagent was dissolved in 20 mM sodium phosphate, pH 7.0, and the latter was dissolved in dimethylsulfoxide, immediately before use. The labeling reagents were applied to the Fab solutions and reacted at room temperature (RT) for 2 hr with stirring. After labeling, removal of the excess reagents, buffer change to 0.1% sodium azide in PBS, and concentration were carried out by filtration with Ultrafree C3LGC columns. Protein assay was carried out with MicroBCA reagents (Pierce) and final protein concentration was adjusted to 1.0 mg/ml. In addition, Zenon biotin-XX mouse IgG 1 and Zenon biotin-XX rabbit IgG labeling kits (Molecular Probes) were used as monovalent secondary antibodies.
Preparation of Soluble Immune Complexes
A primary antibody and a 5-g/ml divalent or monovalent secondary antibody were reacted in 1.5% Blocking Reagent (Roche) in PBS (buffer A) at RT for 2 hr to form a soluble immune complex. Secondary antibodies were labeled with either biotin or DIG.
Immunohistochemical Procedures
Sections were incubated in 0.3% Triton X-100 in PBS at RT for 3 hr, and blocking was performed in 5% skim milk in PBS at RT for 4-6 hr. The sections were incubated with biotin-labeled soluble immune complexes at RT overnight. After washing with PBS, the sections were incubated with AlexaFluor 488-conjugated streptavidin (1:400; Molecular Probes) in buffer A at RT for 2 hr. After washing with PBS, the sections were mounted with the mounting medium Parma Fluor (Thermo Shandon; Pittsburgh, PA) and observed with a fluorescence microscope. Alternatively, IHC was performed by the general sequential procedure as control experiments. After blocking with 5% skim milk in PBS, sections were incubated with a primary antibody in buffer A at RT for 3 hr to overnight. After washing in PBS, the sections were incubated with a 5-g/ml biotin-conjugated divalent or monovalent secondary antibody in buffer A at RT for 3 hr.
The following procedure was as above.
Levels of immunoreactivity were scored as negative ( Ϫ ), equivocal ( Ϯ ), weak ( ϩ ), moderate ( ϩϩ ), and strong ( ϩϩϩ ).
Double-label Fluorescent IHC (Two-step Incubation)
The procedures of double-label fluorescent IHC are summarized in Figure 2 . After blocking with 5% skim milk in PBS, sections were incubated with a first primary antibody in buffer A at RT for 3 hr to overnight. After washing with PBS, the sections were incubated with a 5-g/ml first DIGconjugated monovalent secondary antibody in buffer A for 3 Figure 2 Brief protocol for double-label IHC with identical species-derived primary antibodies. Two-step and one-step incubation procedures are summarized in flow charts. Antibodies were incubated in 1.5% Blocking Reagent in PBS. The concentration of secondary antibodies was 5 g/ml. The concentrations or dilutions of primary antibodies were as described in Table 1 . The incubation was performed at RT for 3 hr to overnight. a Preparation of AR(ϩ) sections was as previously described (Ino 2003) . b DIG and biotin labeling of secondary antibodies are interchangeable in two-step incubation.
hr. After forming a biotin-labeled soluble immune complex with second primary and secondary antibodies, nonspecific mouse immunoglobulin (final concentration 1 mg/ml; Sigma, St Louis, MO) was added to the immune complex to absorb the excess secondary antibody and the solution was incubated at RT for 1 hr. After washing with PBS, the sections were incubated with the immune complex solution at RT for 3 hr. After washing with PBS, the sections were further incubated with AlexaFluor 488-conjugated streptavidin (1:400) and rhodamine-conjugated anti-DIG antibody (1:200; Roche) in buffer A at RT for 2-3 hr. The sections were mounted and observed as above.
Double-label Fluorescent IHC (One-step Incubation)
Two soluble immune complexes were separately formed (secondary antibodies were biotin-and DIG-conjugated monovalent Fab fragments), and the excess secondary antibodies were absorbed with nonspecific mouse immunoglobulin as above. After blocking with 5% skim milk in PBS, sections were incubated with the mixture of the two soluble immune complexes. The following procedure was a two-step incubation.
Results
IHC with Preformed Soluble Immune Complexes
One of the important points in the present method is whether preformed soluble immune complexes consisting of primary and secondary antibodies react to antigens in sections. To address this question, I examined the immunoreactivity of soluble immune complexes using a number of primary antibodies listed in Table 1 , including mouse monoclonal (IgG 1 isotype) and rabbit and guinea pig polyclonal antibodies. Secondary antibodies were composed of divalent antimouse, -rabbit, and -guinea pig IgG(H ϩ L) antibodies, monovalent anti-mouse IgG(H ϩ L) Fab fragments, and monovalent anti-mouse, -rabbit, and -guinea pig IgG(Fc) Fab fragments ( Table 2 ). The anti-IgG(Fc) antibodies specifically recognize the Fc region of an antibody, whereas the anti-IgG(H ϩ L) antibodies recognize the entire IgG molecule, including the heavy and light chains. All the secondary antibodies used in this experiment were labeled with biotin. Sections were from the rat forebrain, brainstem, cerebellum, and DRG tissues. Some of the tissues received AR by heating en bloc before preparation of cryostat sections [AR( ϩ )] and the others did not [AR( Ϫ )].
Before examining the immunoreactivity of the soluble immune complexes and the effects of AR, I confirmed that all the primary antibodies used here showed strong immunoreactivity by the general sequential labeling procedure on AR( ϩ ) sections, although weaker immunoreactivity was observed for NeuN, GFAP (monoclonal and polyclonal), TH, and c-Fos on AR( Ϫ ) sections (data not shown). Equivalent levels of immunoreactivity were observed for the other primary antibodies either on AR( ϩ ) or AR( Ϫ )sections (data not shown). The conditions for AR were fixed in the following experiments (heating at boiling temperature for 3 min in distilled water), because the effects of AR for IHC by the general sequential labeling procedure were remarkable under these conditions.
The results are shown in Table 3 . The anti-CBP and anti-parvalbumin monoclonal antibodies showed moderate immunoreactivity on AR( Ϫ ) sections in the form of soluble immune complex regardless of the sort of the secondary antibodies (CBP was located in Purkinje cells and parvalbumin was located in Purkinje cells, stellate cells, and basket cells in the cerebellum). AR enhanced the immunoreactivity up to equivalent levels demonstrated by the general sequential labeling procedure. On the other hand, as to the anti-NeuN, GFAP, 
a Semiquantitative analysis of immunoreactivity of preformed soluble immune complexes on slide-mounted AR( Ϫ ) or AR( ϩ )sections. Ϫ , negative; Ϯ , equivocal; ϩ , weak; ϩϩ , moderate; ϩϩϩ , strong; NT, not tested. All primary antibodies showed moderate to strong immunoreactivity on AR( ϩ ) or AR( Ϫ )sections by sequential application of primary and secondary antibodies with any secondary antibody. IHC was performed on rat forebrain (NeuN, GFAP, c-Fos, and Egr-1), brainstem (TH), cerebellum (CBP and parvalbumin), and DRG (CGRP, substance P, VR1, and P2X3) sections. and TH monoclonal antibodies, no immunoreactivity was observed with the soluble immune complexes including the divalent secondary antibody on either AR(Ϫ) or AR(ϩ) sections. Even with the immune complex including the anti-IgG(HϩL) Fab or anti-IgG(Fc) Fab, occasionally only weak (NeuN and TH) or no (GFAP) staining was detected on AR(Ϫ) sections. However, AR enhanced the immunoreactivity to moderate levels, although the immunoreactivity was lower than that seen with the general sequential labeling procedure (NeuN and GFAP immunoreactivity was observed in neurons and astrocytes, respectively; TH immunoreactivity was seen in dopaminergic neurons). As to the anti-GFAP polyclonal antibody, although weak immunoreactivity was observed on AR(ϩ) sections with the soluble immune complex including the divalent secondary antibody, the enhancement of the immunoreactivity by AR was more apparent with use of the soluble immune complex including the monovalent secondary antibody. These results indicate that AR was critical for successful immunostaining for NeuN, GFAP (monoclonal and polyclonal), and TH in the form of a soluble immune complex. As to the secondary antibodies, no difference was observed between the anti-IgG(HϩL) Fab and anti-IgG(Fc) Fab. In contrast to the above primary antibodies, no immunoreactivity was observed with the immune complexes for the other primary antibodies (c-Fos, Egr-1, CGRP, substance P, VR1, and P2X3) either on AR(Ϫ) or AR(ϩ) sections, although these antibodies showed moderate to strong immunoreactivity by the general sequential labeling procedure regardless of AR (data not shown; c-Fos and Egr-1 immunoreactivity was observed in nuclei of several neurons; CGRP, substance P, VR1, and P2X3 were located in neurons of the DRG).
The above experiments were performed using the homemade secondary antibodies. I further confirmed the results using commercially available monovalent Fab secondary antibodies (Zenon Biotin-XX mouse IgG 1 and rabbit IgG labeling kits). Almost the same results were obtained with the Zenon secondary antibodies (Table 3) .
In any case, no immunoreactivity was observed in the absence of the primary antibodies (data not shown).
Double-label Fluorescent IHC
I show here two examples of double-label fluorescence IHC. First, the immunoreaction was performed by two-step incubation using the anti-NeuN monoclonal antibody as a first primary antibody, the anti-GFAP monoclonal antibody as a second primary antibody, the DIG-conjugated anti-mouse IgG(Fc) Fab fragment as a first secondary antibody, and the biotin-conjugated anti-mouse IgG(Fc) Fab fragment as a second secondary antibody. To absorb the excess second secondary antibody in the immune complex, 200-fold amounts of nonspecific mouse immunoglobulin were added after the formation of the immune complex. NeuN immunoreactivity was observed in neurons and GFAP immunoreactivity was seen in astrocytes, and no crossreactivity was found ( Figures 3A-3C ). Next, the immunoreaction was performed by one-step incubation using the anti-CBP and parvalbumin monoclonal antibodies as primary antibodies and the DIG-and biotin-conjugated anti-mouse IgG(Fc) Fab fragments as secondary antibodies. The absorption of the excess secondary antibodies was performed as above. As described, CBP is located in Purkinje cells, and parvalbumin is located in Purkinje cells, stellate cells, and basket cells in the cerebellum. Figures 3D-3F show CBP immunoreactivity in Purkinje cells and parvalbumin immunoreactivity in Purkinje cells, stellate cells, and basket cells. Crossreaction with the anti-CBP antibody was not observed in stellate and basket cells ( Figure  3F , arrowheads).
Discussion
To extend the possible applications for double-label IHC, the methodology using soluble immune complexes comprised of monovalent secondary antibodies, which enables the use of identical species-derived primary antibodies, seems to be excellent in principle. However, it was revealed from the present study that there is a crucial problem in practice. The immunoreactivity of soluble immune complexes against antigens in sections is sometimes greatly reduced and often completely lost. Among the antibodies I tested here, only the first group of the antibodies (anti-CBP and anti-parvalbumin antibodies) showed sufficient levels of immunoreactivity in AR(Ϫ) sections. Although the second group of the antibodies (anti-NeuN, anti-GFAP and anti-TH antibodies) showed little or no immunoreactivity in AR(Ϫ) sections, greatly improved immunoreactivity was observed in AR(ϩ) sections. In contrast, the third group of the antibodies (the other antibodies) showed no immumerged in F. The first immune complex consisted of the mouse anti-CDP monoclonal antibody and DIG-conjugated anti-mouse IgG(Fc) Fab fragment, and the second of the anti-parvalbumin monoclonal antibody and biotin-conjugated anti-mouse IgG(Fc) Fab fragment. The immune complexes were separately formed and then simultaneously applied to the section. Purkinje cells (F, arrows) were positive for both CBP and parvalbumin, while stellate cells and basket cells (F, arrowheads) were positive only for parvalbumin. Signal was detected with the rhodamine-conjugated anti-DIG Fab fragment and AlexaFluor 488-conjugated streptavidin. Bar ϭ 50 m.
